50 million seniors age 60 and over to get Zostavax to prevent shingles

  New recommendations will call for about 50 million seniors age 60 and over to get Zostavax to prevent shingles.

  This new vaccine reduces the RELATIVE risk of shingles by about 50% and the ABSOLUTE risk by 1.7%. It also reduces the relative risk of postherpetic neuralgia by 67%...since fewer people get shingles.

  There are no significant side effects for most people.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote